Commercial Five things for pharma marketers to know: Friday, April 29, 2016

Five things for pharma marketers to know: Friday, April 29, 2016

Harvoni and Sovaldi growth begins to slow; drugmakers spend billions to buy developers of cancer therapies; Valeant discloses new investigations

Commercial Rolling with the Punches as Marketing Evolves

Rolling with the Punches as Marketing Evolves

Some 30% of the physicians in the U.S. sold their practices, which in turn commensurately reduced the number of physicians who are willing and able to be called on by sales reps.

Commercial Five things for pharma marketers to know: Monday, April 11, 2016

Five things for pharma marketers to know: Monday, April 11, 2016

Valeant's missteps derailed Addyi; Biogen reportedly considers selling its hemophilia treatment portfolio; Roche's PD-LI inhibitor granted Priority Review

Commercial MannKind reworks commercial strategy for Afrezza

MannKind reworks commercial strategy for Afrezza

After buying back the rights to the therapy, the biopharmaceutical company is building a endocrinology sales force and hiring a new advertising agency.

Commercial Five things for pharma marketers to know: Tuesday, April 5, 2016

Five things for pharma marketers to know: Tuesday, April 5, 2016

Valeant terminates Addyi's sales force; the Treasury Department issues new tax-inversion rules; MannKind buys back its marketing rights to Afrezza

Commercial Drugmakers move to counteract expiring patents with new respiratory drugs

Drugmakers move to counteract expiring patents with new respiratory drugs

Symptom-driven care is falling out of fa­vor with lung-drug leaders increasingly interested in assigning optimal treatment approaches to patient conditions.

Commercial Top 25 respiratory products, 2014-2015

Top 25 respiratory products, 2014-2015

GlaxoSmithKline's Advair brought in $4.8 billion in U.S. sales in 2015, edging out Boehringer Ingelheim's Spiriva Handihaler ($3.4 billion) and AstraZeneca's Symbicort ($2.6 billion).

Commercial The truth about a doctor's day: know-it-all patients and no time for lunch

The truth about a doctor's day: know-it-all patients and no time for lunch

There are big changes underway in the doctor-patient relationship, a study suggests, and it's a new reality to which biopharma must adjust.

Commercial Five things for pharma marketers to know: Thursday, March 17, 2016

Five things for pharma marketers to know: Thursday, March 17, 2016

Entresto's sales are still lower than expected; GSK CEO Witty to retire in 2017; tech assistants sometimes fail to account for women's health needs

Commercial Xifaxan misses sales mark amidst Valeant leadership changes

Xifaxan misses sales mark amidst Valeant leadership changes

IBS drug Xifaxan missed the company's sales projection for the fourth quarter of 2015 by $180 million.